Saudi Arabia in-vitro Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The saudi arabia in-vitro diagnostics market size is expected to grow from USD 1.05 billion in 2025 to USD 1.09 billion in 2026 and is forecast to reach USD 1.31 billion by 2031 at 3.81% CAGR over 2026-2031. This report is Segmented by Test Type (Clinical Chemistry, Molecular Diagnostics, Immuno-Diagnostics, and More), Product (Instruments, Reagents and Kits), Usability (Disposable IVD Devices and Re-Usable IVD Devices), Application (Infectious Disease, Diabetes, and More), and End-User (Diagnostic Laboratories, Hospitals and More). The Market Forecasts are Provided in Terms of Value (USD).

Saudi Arabia In-vitro Diagnostics Market Trends and Insights

Escalating Chronic Disease Prevalence

Saudi Arabia’s diabetic population is projected to grow from 2.69 million in 2020 to 4.21 million by 2030, boosting demand for HbA1c, lipid, and tumor marker panels. King Faisal Specialist Hospital’s AI-driven hematology lab launched in 2024 processes 9,000 flow tests annually, illustrating nationwide upgrades that support precision hematology. The Ayenati network now links 1,194 reference labs and has logged 5.3 million samples, creating a national data backbone for population screening. ISO 15189 accreditation is becoming a gatekeeper for public tenders, concentrating volumes within labs that maintain rigorous quality systems.

Growing Government Healthcare Expenditure and Vision 2030 Investments

Health-sector budgets rose to SAR 214 billion (USD 57.1 billion) in 2024 and are slated for SAR 260 billion (USD 69.3 billion) by 2026, funneling funds into lab modernization, digital pathology, and telemedicine nodes. Privatization plans covering 290 public hospitals will fragment procurement and widen access for specialty-test vendors. Lifera Omics, a November 2023 joint venture with CENTOGENE, positions the Kingdom to localize multiomic testing, reducing outbound sample flows. NPHIES now covers 31 million insured residents, mandating real-time claims adjudication that rewards digitized labs.

Limited Reimbursement for Advanced Molecular Assays

The Council of Cooperative Health Insurance reimburses insulin pumps under strict criteria but has not published guidelines for next-generation sequencing or liquid-biopsy assays, leaving most advanced molecular tests self-pay. Fragmented private-payer policies force suppliers into piecemeal negotiations, inflating administrative costs and slowing adoption. Penetration of insulin pumps among type 1 diabetics remains below 3%, underscoring how eligibility rules can suppress device uptake even when clinical value is clear. Absent a national medical-device formulary, coverage decisions vary widely, perpetuating regional inequities in access to precision diagnostics.

Other drivers and restraints analyzed in the detailed report include:

• Rapid Expansion of Private Healthcare Infrastructure
• Rising Demand for Personalized and Genomic Diagnostics
• Stringent Regulatory Approval Processes

Segment Analysis

Clinical chemistry commanded 35.1% revenue in 2025 on the strength of high-volume liver-function and lipid panels. Despite this, the Saudi Arabia in-vitro diagnostics market size for molecular assays is projected to expand at a 5.33% CAGR through 2031, the fastest among test types. Uptake is fueled by syndromic infectious-disease panels and oncology profilers required for targeted therapies. King Faisal’s automated flow cytometry track exemplifies a nationwide pivot toward AI-assisted hematology that reduces manual microscopy and enriches immunophenotyping depth. Immuno-diagnostics remains essential but faces margin compression under NUPCO’s bulk-purchase pricing caps. Hematology platforms now bundle digital image analysis, optimizing throughput amid staffing shortages.

Workflow efficiency differentiates suppliers. Beckman Coulter’s DxC 700 AU analyzer cut processing steps by 30%, aligning with labs’ need to handle rising sample loads without headcount growth. National interoperability mandates through the Ayenati network further accelerate retirement of legacy instruments lacking digital connectivity. Overall, molecular diagnostics’ high growth rate will rebalance the Saudi Arabia in-vitro diagnostics market toward precision tests while preserving clinical chemistry’s foundational role.

Reagents and kits held 68.12% revenue in 2025, reflecting consumable annuity economics that lock customers into proprietary chemistries over instrument lifespans. Yet instruments are expected to record a 5.66% CAGR by 2031 as labs modernize under Vision 2030. Al Borg’s twin reference labs required next-generation sequencers, high-throughput chemistry tracks, and digital pathology scanners, all of which create durable reagent pull-through. The Saudi Arabia in-vitro diagnostics market share for high-value specialty reagents - flow cytometry cocktails, liquid-biopsy kits - will outpace commoditized routine chemistries, buffering suppliers against pricing pressure.

Suppliers now bundle predictive maintenance and remote diagnostics; Beckman Coulter’s “3 & 60” concept allows part changes in three steps within 60 seconds, minimizing downtime where field engineers are scarce. Privatization of 290 hospitals will transfer procurement authority from centralized NUPCO tenders to emerging group-purchasing organizations, favoring vendors offering flexible financing and localized service.

Complete Report Scope:

• By Test Type
  • Clinical Chemistry
  • Molecular Diagnostics
  • Immuno-Diagnostics
  • Hematology
  • Other Test Types
• By Product
  • Instruments
  • Reagents & Kits
• By Usability
  • Disposable IVD Devices
  • Re-Usable IVD Devices
• By Application
  • Infectious Disease
  • Diabetes
  • Oncology
  • Cardiology
  • Other Applications
• By End-User
  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Home-Care & POC Settings
  • Other End-Users

List of Companies Covered in this Report:

• Abbott Laboratories
• Al Borg Diagnostics
• Al Razi Medical Labs
• Becton Dickinson (BD)
• Bio-Rad Laboratories
• bioMérieux
• Danaher (Beckman Coulter & Cepheid)
• Dammam Regional Laboratory
• DiaSorin
• Fujifilm Wako
• Illumina
• Intelligent Bio Solutions / QabasTech
• King Faisal Specialist Hospital Labs
• Lifera (Saudi PIF Biotech Arm)
• Mindray Bio-Medical Electronics
• QIAGEN
• Randox Laboratories
• Roche
• Saudi Diagnostic Laboratory Co.
• Siemens Healthineers
• Sysmex Saudi LLC
• Thermo Fisher Scientific
• Tosoh
• Werfen

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support